The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | Molecular target therapy in pancreatic and liver cancer

Name: Molecular target therapy in pancreatic and liver cancer
Uploaded: 2019-10-18T14:09:45Z
Duration: 3 min 45 s
Description: Hani Babiker, MD, The University of Arizona, Tucson, AZ, talks about various updates in the fields of pancreatic and liver cancer, with a focus on molecular-based target therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Hani Babiker • 18 Oct 2019

ESMO 2019

Gastrointestinal Cancer Liver Cancer Pancreatic Cancer Atezolizumab Bevacizumab Lenvatinib Olaparib Pembrolizumab

Hani Babiker, MD, The University of Arizona, Tucson, AZ, talks about various updates in the fields of pancreatic and liver cancer, with a focus on molecular-based target therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.